Prevalence and correlates of highly active antiretroviral therapy switching in the Women's Interagency HIV Study

Lynn M. Kirstein, Ruth M. Greenblatt, Kathryn Anastos, Alexandra Levine, Audrey L. French, Howard Minkoff, Sylvia Silver, Stephen J Gange

Research output: Contribution to journalArticle

Abstract

Objective: The purpose of this study was to describe the variability in highly active antiretroviral therapy (HAART) regimens over time, the extent to which individuals switch, and the characteristics of those who are switching. Methods: We evaluated data collected between 1994 and 2000 from 1056 HIV-positive women enrolled in the Women's Interagency HIV Study (WIHS) who reported initiating HAART. We described the variability and prevalence of changes in HAART regimens between semiannual visits, estimated time to switch using Kaplan-Meier methods, investigated factors associated with a first switch using Cox proportional hazards models, and compared disease markers among women switching or remaining on unchanged HAART regimens. Results: We demonstrated a 13-fold increase in the number of unique HAART regimens reported since mid-1996 and showed that the amount of time spent on the first, second, or third regimen is similar, with an 8-month median time to switching or discontinuing the initial HAART regimen. Women who switched had a lower mean CD4 cell count and were more likely to have HIV RNA levels greater than 400 copies/mL. Overall, the percentage of women switching decreased over the course of follow-up (to 37% in September 2000), although the percentage discontinuing therapy altogether increased 2-fold. Conclusion: Our findings on the relatively high rate of HAART switching emphasize the complexity of managing and evaluating these therapies.

Original languageEnglish (US)
Pages (from-to)495-503
Number of pages9
JournalJournal of Acquired Immune Deficiency Syndromes
Volume29
Issue number5
StatePublished - 2002

Fingerprint

Highly Active Antiretroviral Therapy
HIV
CD4 Lymphocyte Count
Proportional Hazards Models
RNA
Therapeutics

Keywords

  • Antiretroviral therapy
  • Discontinuation
  • HAART
  • Modification
  • Switching

ASJC Scopus subject areas

  • Virology
  • Immunology

Cite this

Prevalence and correlates of highly active antiretroviral therapy switching in the Women's Interagency HIV Study. / Kirstein, Lynn M.; Greenblatt, Ruth M.; Anastos, Kathryn; Levine, Alexandra; French, Audrey L.; Minkoff, Howard; Silver, Sylvia; Gange, Stephen J.

In: Journal of Acquired Immune Deficiency Syndromes, Vol. 29, No. 5, 2002, p. 495-503.

Research output: Contribution to journalArticle

Kirstein, LM, Greenblatt, RM, Anastos, K, Levine, A, French, AL, Minkoff, H, Silver, S & Gange, SJ 2002, 'Prevalence and correlates of highly active antiretroviral therapy switching in the Women's Interagency HIV Study', Journal of Acquired Immune Deficiency Syndromes, vol. 29, no. 5, pp. 495-503.
Kirstein, Lynn M. ; Greenblatt, Ruth M. ; Anastos, Kathryn ; Levine, Alexandra ; French, Audrey L. ; Minkoff, Howard ; Silver, Sylvia ; Gange, Stephen J. / Prevalence and correlates of highly active antiretroviral therapy switching in the Women's Interagency HIV Study. In: Journal of Acquired Immune Deficiency Syndromes. 2002 ; Vol. 29, No. 5. pp. 495-503.
@article{47b3560270224012a5faf179027771f6,
title = "Prevalence and correlates of highly active antiretroviral therapy switching in the Women's Interagency HIV Study",
abstract = "Objective: The purpose of this study was to describe the variability in highly active antiretroviral therapy (HAART) regimens over time, the extent to which individuals switch, and the characteristics of those who are switching. Methods: We evaluated data collected between 1994 and 2000 from 1056 HIV-positive women enrolled in the Women's Interagency HIV Study (WIHS) who reported initiating HAART. We described the variability and prevalence of changes in HAART regimens between semiannual visits, estimated time to switch using Kaplan-Meier methods, investigated factors associated with a first switch using Cox proportional hazards models, and compared disease markers among women switching or remaining on unchanged HAART regimens. Results: We demonstrated a 13-fold increase in the number of unique HAART regimens reported since mid-1996 and showed that the amount of time spent on the first, second, or third regimen is similar, with an 8-month median time to switching or discontinuing the initial HAART regimen. Women who switched had a lower mean CD4 cell count and were more likely to have HIV RNA levels greater than 400 copies/mL. Overall, the percentage of women switching decreased over the course of follow-up (to 37{\%} in September 2000), although the percentage discontinuing therapy altogether increased 2-fold. Conclusion: Our findings on the relatively high rate of HAART switching emphasize the complexity of managing and evaluating these therapies.",
keywords = "Antiretroviral therapy, Discontinuation, HAART, Modification, Switching",
author = "Kirstein, {Lynn M.} and Greenblatt, {Ruth M.} and Kathryn Anastos and Alexandra Levine and French, {Audrey L.} and Howard Minkoff and Sylvia Silver and Gange, {Stephen J}",
year = "2002",
language = "English (US)",
volume = "29",
pages = "495--503",
journal = "Journal of Acquired Immune Deficiency Syndromes",
issn = "1525-4135",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Prevalence and correlates of highly active antiretroviral therapy switching in the Women's Interagency HIV Study

AU - Kirstein, Lynn M.

AU - Greenblatt, Ruth M.

AU - Anastos, Kathryn

AU - Levine, Alexandra

AU - French, Audrey L.

AU - Minkoff, Howard

AU - Silver, Sylvia

AU - Gange, Stephen J

PY - 2002

Y1 - 2002

N2 - Objective: The purpose of this study was to describe the variability in highly active antiretroviral therapy (HAART) regimens over time, the extent to which individuals switch, and the characteristics of those who are switching. Methods: We evaluated data collected between 1994 and 2000 from 1056 HIV-positive women enrolled in the Women's Interagency HIV Study (WIHS) who reported initiating HAART. We described the variability and prevalence of changes in HAART regimens between semiannual visits, estimated time to switch using Kaplan-Meier methods, investigated factors associated with a first switch using Cox proportional hazards models, and compared disease markers among women switching or remaining on unchanged HAART regimens. Results: We demonstrated a 13-fold increase in the number of unique HAART regimens reported since mid-1996 and showed that the amount of time spent on the first, second, or third regimen is similar, with an 8-month median time to switching or discontinuing the initial HAART regimen. Women who switched had a lower mean CD4 cell count and were more likely to have HIV RNA levels greater than 400 copies/mL. Overall, the percentage of women switching decreased over the course of follow-up (to 37% in September 2000), although the percentage discontinuing therapy altogether increased 2-fold. Conclusion: Our findings on the relatively high rate of HAART switching emphasize the complexity of managing and evaluating these therapies.

AB - Objective: The purpose of this study was to describe the variability in highly active antiretroviral therapy (HAART) regimens over time, the extent to which individuals switch, and the characteristics of those who are switching. Methods: We evaluated data collected between 1994 and 2000 from 1056 HIV-positive women enrolled in the Women's Interagency HIV Study (WIHS) who reported initiating HAART. We described the variability and prevalence of changes in HAART regimens between semiannual visits, estimated time to switch using Kaplan-Meier methods, investigated factors associated with a first switch using Cox proportional hazards models, and compared disease markers among women switching or remaining on unchanged HAART regimens. Results: We demonstrated a 13-fold increase in the number of unique HAART regimens reported since mid-1996 and showed that the amount of time spent on the first, second, or third regimen is similar, with an 8-month median time to switching or discontinuing the initial HAART regimen. Women who switched had a lower mean CD4 cell count and were more likely to have HIV RNA levels greater than 400 copies/mL. Overall, the percentage of women switching decreased over the course of follow-up (to 37% in September 2000), although the percentage discontinuing therapy altogether increased 2-fold. Conclusion: Our findings on the relatively high rate of HAART switching emphasize the complexity of managing and evaluating these therapies.

KW - Antiretroviral therapy

KW - Discontinuation

KW - HAART

KW - Modification

KW - Switching

UR - http://www.scopus.com/inward/record.url?scp=0036240655&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036240655&partnerID=8YFLogxK

M3 - Article

VL - 29

SP - 495

EP - 503

JO - Journal of Acquired Immune Deficiency Syndromes

JF - Journal of Acquired Immune Deficiency Syndromes

SN - 1525-4135

IS - 5

ER -